Pfizer selects third target under research collaboration with Theraclone
The collaboration leverages Theraclone I-STAR technology, which is used to screen and identify novel human antibodies to pathogenic agents and endogenous therapeutic targets, to discover monoclonal antibodies against
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.